Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications Company to host conference call and webcast today, May 16, at 8:30 AM ET OCALA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported its financial results for the first quarter 2024. As previously announced, the Company will host a conference call and webcast today, Thursday, May 16, 2024, at 8:30 AM ET (details below ...

Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications Company to host conference call and webcast today, May 16, at 8:30 AM ET OCALA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported its financial results for the first quarter 2024. As previously announced, the Company will host a conference call and webcast today, Thursday, May 16, 2024, at 8:30 AM ET (det ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 Commission File Number: 001-27072 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 52-0845822 (State or other jurisdiction of (I.R.S. Employer incorporation or organiza ...

OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company’s Q1 2024 operational and financial results on Thursday, May 16, 2024, at 8:30 AM ET. The call will be hosted by members of AIM’s leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer. Interested participants and investors may access the conference ca ...

OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") announced today that management will host a conference call and webcast to discuss the Company's Q1 2024 operational and financial results on Thursday, May 16, 2024, at 8:30 AM ET. The call will be hosted by members of AIM's leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer. Interested participants and investors may access the conference call by dial ...

OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen® (rintatolimod), AIM's dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. AIM Chief Executive Officer Thomas K. Equels commented, "We remain focused on operational execution and the successful continued production of our commercial-size ...

佛罗里达州奥卡拉, April 11, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)（以下简称“AIM”）今日宣布了顶线中期数据，表明 Ampligen (rintatolimod) 和 Keytruda (pembrolizumab) 的联合用药在治疗复发性卵巢癌方面可能具有强大的协同作用。研究者由此得出结论，认为与单独使用 pembrolizumab 相比，该联合疗法对于治疗该疾病可能有效得多。 有关“全身免疫检查点阻断和腹腔免疫化疗法治疗复发性卵巢癌”研究的更多细节请访问 ClinicalTrials.gov: NCT03734692。此外，在其他临床试验中也发现了支持这种协同增强作用的免疫学特征，包括胰腺癌 (1,2) 转移性三阴性乳腺癌和结直肠癌肝转移。 Ampligen 是一种双链 RNA 候选产品，通过存在于多种免疫细胞、上皮细胞和大多数实体瘤上的 TLR-3 受体发挥作用。在正在进行的、由研究者发起的 2 期单臂疗效/安全性试验中，匹兹堡大学医疗中心的研究人员发现，在铂敏感复发性卵巢癌受试者中联合使用 Amp ...

OCALA, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM") today announced top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda (pembrolizumab) in the treatment of recurrent ovarian cancer may have a powerful synergistic effect, leading the investigator to conclude that the combination therapy could be far more effective than pembrolizumab alone as a therapy for the disease. See further details on the study "Systemic Immune Checkpoint Blockade and ...

业绩总结 - 公司在2023年取得了显著进展，展示了日益增长的高度有前途、一致积极数据的成果[10] - 公司在肿瘤学领域的积极数据成为与专业肿瘤学业务发展公司Azenova合作的催化剂[12] - 公司成功扩大和确保了在肿瘤学领域的Ampligen专利资产[14] 未来展望 - 预计DURIPANC研究的第一阶段将在2024年夏季完成[30] - 公司相信Ampligen不仅仅是一种特定癌症的治疗方法，而是适用于多种类型的治疗[35] - 公司相信通过DURIPANC研究在胰腺癌中将证实Ampligen与免疫检查点抑制剂具有显著的协同效应[36] 新产品和新技术研发 - DURIPANC研究结合Ampligen和durvalumab作为FOLFIRINOX后的治疗[29] - Ampligen在不同实体瘤中的效果，通过与toll样受体3结合起作用[32] - Ampligen通过增加免疫生物标志物促使免疫系统攻击肿瘤[34] 市场扩张和并购 - 公司正在招聘和开设新站点，目前的站点仍在接受报名并筛选潜在候选人[28] - 欧洲预计在年底前将有人员参与治疗[50] - 美国由于标准护理的差异，导致招募困难[51] 负面信息 - 期望在2024年不再有高额的法律费用[71] - 美国有数百万人预计会患上严重的后COVID慢性疲劳症状[75] - 目前仅在美国就有大约400万潜在患者[75]

Ampligen治疗慢性疲劳综合征和癌症 - Ampligen®在阿根廷获得销售批准，用于治疗严重慢性疲劳综合征[39] - Ampligen®具有广谱抗病毒和抗癌特性，可能是一种新型药物[40] - FDA授权AMP-511开放标签扩展访问治疗方案，允许患有慢性疲劳综合征的患者接触Ampligen[41] - Ampligen在癌症免疫治疗中表现出潜力，与匹兹堡大学合作进行研究[50] - Ampligen作为治疗ME/CFS的旗舰药物，进行了多项研究和临床试验[76] Ampligen抗病毒特性 - Ampligen在动物实验中显示出对SARS-CoV-1的抗病毒特性，并在研究中展现出对SARS-CoV-2的保护性存活效果[69] - Ampligen在对抗SARS-CoV-2病毒方面展现出潜在的抗病毒效果[71] - Ampligen与干扰素α联合治疗被FDA授权用于癌症患者COVID-19感染的临床试验[72] - Ampligen被用于治疗长期COVID-19患者和进行临床试验[73] - 获得美国专利，用于预防或减少宿主动物感染禽流感病毒[75] Ampligen临床试验和研究合作 - 进行了多项Ampligen临床试验，测试肿瘤微环境是否可以重编程以增加癌症免疫治疗的有效性[50] - 开展了胰腺癌试验，预计将在美国和欧洲的30个中心招募约90名受试者[50] - 发布了关于晚期复发性卵巢癌的研究结果，显示Ampligen在肿瘤微环境中的作用[52] - 公司与意大利卡利亚里大学合作研究Ampligen的效果和能力[78] - 公司申请了Ampligen作为可能减缓、停止或逆转阿尔茨海默病进展的专利[78] Ampligen生产和合作 - 公司与Jubilant HollisterStier合作，生产了两批Ampligen，用于美国的CFS项目和扩展的肿瘤临床试验[80] - 公司与Pii签订了“填充和完成”协议，以增强Ampligen的生产能力[80] - 公司在新泽西生物科技中心租赁了一座面积为5,210平方英尺的研发设施[82] - 公司与Sterling Pharma Solutions签订了协议，用于制造Poly I和Poly C12U聚核苷酸，以生产Ampligen的聚合物前体[82]